Overview

A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD

Status:
Recruiting
Trial end date:
2027-04-30
Target enrollment:
Participant gender:
Summary
The study is designed for multi-center,randomized,double-masked,active-contralled study to evaluate effective and security of intravitreal injection of IBI302 in subjects with neovascular age-related macular degeneration.
Phase:
Phase 3
Details
Lead Sponsor:
Innovent Biologics (Suzhou) Co. Ltd.
Treatments:
Aflibercept